Progress in Anti-Cancer Chemotherapy:
This is the fourth volume of our series Progress in Anti-cancer Therapy. For the past four years we have taken the challenge to select each year, some of the most interesting topics on the wide field of oncology. As usual, this volume continues the tradition and covers five cancers (breast, prostate...
Gespeichert in:
| Weitere Verfasser: | , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Paris
Springer Paris
2000
|
| Schriftenreihe: | Progress in Anti-Cancer Chemotherapy
4 |
| Schlagworte: | |
| Online-Zugang: | UBR01 Volltext |
| Zusammenfassung: | This is the fourth volume of our series Progress in Anti-cancer Therapy. For the past four years we have taken the challenge to select each year, some of the most interesting topics on the wide field of oncology. As usual, this volume continues the tradition and covers five cancers (breast, prostate, bladder, lym phoma and ovarian), the role of HIV and HTLV in cancer, as well as some deve lopmental pharmacology and behavioral issues. This year, we have particularly focused our attention on one of the most com mon (although rarely addressed) cancer accounting for more than 315,00 newly diagnosed cases and 41,000 cancer-related deaths annually (Landis SH et al., 1999) : prostate cancer. Five chapters address some of the issues concerning this disease. The chap ter by Schroder describes the hopes and pitfalls of early detection of prostate cancer. It reviews the literature on screening studies that have been performed both in the US and in Europe. These studies suggest that cancer mortality could be reduced by screening for prostate cancer, mostly through PSA testing. However, the effectiveness of early detection still needs to be definitely confir med and ongoing randomized studies are described, the results of which will probably help the medical community determine the worth of PSA-based scree ning for prostate cancer. On the same hand, the paper from von Eschenbach is reviewing the clinical problems that are related this disease |
| Beschreibung: | 1 Online-Ressource (X, 270 p. 6 illus) |
| ISBN: | 9782817809205 |
| DOI: | 10.1007/978-2-8178-0920-5 |
Internformat
MARC
| LEADER | 00000nmm a2200000zcb4500 | ||
|---|---|---|---|
| 001 | BV046145734 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 190905s2000 |||| o||u| ||||||eng d | ||
| 020 | |a 9782817809205 |9 978-2-8178-0920-5 | ||
| 024 | 7 | |a 10.1007/978-2-8178-0920-5 |2 doi | |
| 035 | |a (ZDB-2-SME)978-2-8178-0920-5 | ||
| 035 | |a (OCoLC)1119091231 | ||
| 035 | |a (DE-599)BVBBV046145734 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 082 | 0 | |a 616.994 |2 23 | |
| 245 | 1 | 0 | |a Progress in Anti-Cancer Chemotherapy |c edited by David Khayat, Gabriel N. Hortobagyi |
| 264 | 1 | |a Paris |b Springer Paris |c 2000 | |
| 300 | |a 1 Online-Ressource (X, 270 p. 6 illus) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Progress in Anti-Cancer Chemotherapy |v 4 | |
| 520 | |a This is the fourth volume of our series Progress in Anti-cancer Therapy. For the past four years we have taken the challenge to select each year, some of the most interesting topics on the wide field of oncology. As usual, this volume continues the tradition and covers five cancers (breast, prostate, bladder, lym phoma and ovarian), the role of HIV and HTLV in cancer, as well as some deve lopmental pharmacology and behavioral issues. This year, we have particularly focused our attention on one of the most com mon (although rarely addressed) cancer accounting for more than 315,00 newly diagnosed cases and 41,000 cancer-related deaths annually (Landis SH et al., 1999) : prostate cancer. Five chapters address some of the issues concerning this disease. The chap ter by Schroder describes the hopes and pitfalls of early detection of prostate cancer. It reviews the literature on screening studies that have been performed both in the US and in Europe. These studies suggest that cancer mortality could be reduced by screening for prostate cancer, mostly through PSA testing. However, the effectiveness of early detection still needs to be definitely confir med and ongoing randomized studies are described, the results of which will probably help the medical community determine the worth of PSA-based scree ning for prostate cancer. On the same hand, the paper from von Eschenbach is reviewing the clinical problems that are related this disease | ||
| 650 | 4 | |a Oncology | |
| 650 | 4 | |a Cancer Research | |
| 650 | 4 | |a Oncology | |
| 650 | 4 | |a Oncology | |
| 650 | 0 | 7 | |a Chemotherapie |0 (DE-588)4127083-6 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Pharmakotherapie |0 (DE-588)4076066-2 |2 gnd |9 rswk-swf |
| 655 | 7 | |8 1\p |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |D s |
| 689 | 0 | 1 | |a Pharmakotherapie |0 (DE-588)4076066-2 |D s |
| 689 | 0 | |8 2\p |5 DE-604 | |
| 689 | 1 | 0 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |D s |
| 689 | 1 | 1 | |a Chemotherapie |0 (DE-588)4127083-6 |D s |
| 689 | 1 | |8 3\p |5 DE-604 | |
| 700 | 1 | |a Khayat, David |4 edt | |
| 700 | 1 | |a Hortobagyi, Gabriel N. |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9782287596926 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9782817809212 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-2-8178-0920-5 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-SME | ||
| 940 | 1 | |q ZDB-2-SME_1990/2004 | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-031525919 | ||
| 883 | 1 | |8 1\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 883 | 1 | |8 2\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 883 | 1 | |8 3\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 966 | e | |u https://doi.org/10.1007/978-2-8178-0920-5 |l UBR01 |p ZDB-2-SME |q ZDB-2-SME_1990/2004 |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804180482776104960 |
|---|---|
| any_adam_object | |
| author2 | Khayat, David Hortobagyi, Gabriel N. |
| author2_role | edt edt |
| author2_variant | d k dk g n h gn gnh |
| author_facet | Khayat, David Hortobagyi, Gabriel N. |
| building | Verbundindex |
| bvnumber | BV046145734 |
| collection | ZDB-2-SME |
| ctrlnum | (ZDB-2-SME)978-2-8178-0920-5 (OCoLC)1119091231 (DE-599)BVBBV046145734 |
| dewey-full | 616.994 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.994 |
| dewey-search | 616.994 |
| dewey-sort | 3616.994 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| doi_str_mv | 10.1007/978-2-8178-0920-5 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03774nmm a2200601zcb4500</leader><controlfield tag="001">BV046145734</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">190905s2000 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9782817809205</subfield><subfield code="9">978-2-8178-0920-5</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-2-8178-0920-5</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SME)978-2-8178-0920-5</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1119091231</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046145734</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.994</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Progress in Anti-Cancer Chemotherapy</subfield><subfield code="c">edited by David Khayat, Gabriel N. Hortobagyi</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Paris</subfield><subfield code="b">Springer Paris</subfield><subfield code="c">2000</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (X, 270 p. 6 illus)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Progress in Anti-Cancer Chemotherapy</subfield><subfield code="v">4</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This is the fourth volume of our series Progress in Anti-cancer Therapy. For the past four years we have taken the challenge to select each year, some of the most interesting topics on the wide field of oncology. As usual, this volume continues the tradition and covers five cancers (breast, prostate, bladder, lym phoma and ovarian), the role of HIV and HTLV in cancer, as well as some deve lopmental pharmacology and behavioral issues. This year, we have particularly focused our attention on one of the most com mon (although rarely addressed) cancer accounting for more than 315,00 newly diagnosed cases and 41,000 cancer-related deaths annually (Landis SH et al., 1999) : prostate cancer. Five chapters address some of the issues concerning this disease. The chap ter by Schroder describes the hopes and pitfalls of early detection of prostate cancer. It reviews the literature on screening studies that have been performed both in the US and in Europe. These studies suggest that cancer mortality could be reduced by screening for prostate cancer, mostly through PSA testing. However, the effectiveness of early detection still needs to be definitely confir med and ongoing randomized studies are described, the results of which will probably help the medical community determine the worth of PSA-based scree ning for prostate cancer. On the same hand, the paper from von Eschenbach is reviewing the clinical problems that are related this disease</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer Research</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology </subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Chemotherapie</subfield><subfield code="0">(DE-588)4127083-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmakotherapie</subfield><subfield code="0">(DE-588)4076066-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="8">1\p</subfield><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Pharmakotherapie</subfield><subfield code="0">(DE-588)4076066-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="8">2\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Chemotherapie</subfield><subfield code="0">(DE-588)4127083-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="8">3\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Khayat, David</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hortobagyi, Gabriel N.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9782287596926</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9782817809212</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-2-8178-0920-5</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SME</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SME_1990/2004</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-031525919</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">2\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">3\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-2-8178-0920-5</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-2-SME</subfield><subfield code="q">ZDB-2-SME_1990/2004</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| genre | 1\p (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV046145734 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T08:36:28Z |
| institution | BVB |
| isbn | 9782817809205 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-031525919 |
| oclc_num | 1119091231 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online-Ressource (X, 270 p. 6 illus) |
| psigel | ZDB-2-SME ZDB-2-SME_1990/2004 ZDB-2-SME ZDB-2-SME_1990/2004 |
| publishDate | 2000 |
| publishDateSearch | 2000 |
| publishDateSort | 2000 |
| publisher | Springer Paris |
| record_format | marc |
| series2 | Progress in Anti-Cancer Chemotherapy |
| spelling | Progress in Anti-Cancer Chemotherapy edited by David Khayat, Gabriel N. Hortobagyi Paris Springer Paris 2000 1 Online-Ressource (X, 270 p. 6 illus) txt rdacontent c rdamedia cr rdacarrier Progress in Anti-Cancer Chemotherapy 4 This is the fourth volume of our series Progress in Anti-cancer Therapy. For the past four years we have taken the challenge to select each year, some of the most interesting topics on the wide field of oncology. As usual, this volume continues the tradition and covers five cancers (breast, prostate, bladder, lym phoma and ovarian), the role of HIV and HTLV in cancer, as well as some deve lopmental pharmacology and behavioral issues. This year, we have particularly focused our attention on one of the most com mon (although rarely addressed) cancer accounting for more than 315,00 newly diagnosed cases and 41,000 cancer-related deaths annually (Landis SH et al., 1999) : prostate cancer. Five chapters address some of the issues concerning this disease. The chap ter by Schroder describes the hopes and pitfalls of early detection of prostate cancer. It reviews the literature on screening studies that have been performed both in the US and in Europe. These studies suggest that cancer mortality could be reduced by screening for prostate cancer, mostly through PSA testing. However, the effectiveness of early detection still needs to be definitely confir med and ongoing randomized studies are described, the results of which will probably help the medical community determine the worth of PSA-based scree ning for prostate cancer. On the same hand, the paper from von Eschenbach is reviewing the clinical problems that are related this disease Oncology Cancer Research Oncology Chemotherapie (DE-588)4127083-6 gnd rswk-swf Krebs Medizin (DE-588)4073781-0 gnd rswk-swf Pharmakotherapie (DE-588)4076066-2 gnd rswk-swf 1\p (DE-588)4143413-4 Aufsatzsammlung gnd-content Krebs Medizin (DE-588)4073781-0 s Pharmakotherapie (DE-588)4076066-2 s 2\p DE-604 Chemotherapie (DE-588)4127083-6 s 3\p DE-604 Khayat, David edt Hortobagyi, Gabriel N. edt Erscheint auch als Druck-Ausgabe 9782287596926 Erscheint auch als Druck-Ausgabe 9782817809212 https://doi.org/10.1007/978-2-8178-0920-5 Verlag URL des Erstveröffentlichers Volltext 1\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk 2\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk 3\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk |
| spellingShingle | Progress in Anti-Cancer Chemotherapy Oncology Cancer Research Oncology Chemotherapie (DE-588)4127083-6 gnd Krebs Medizin (DE-588)4073781-0 gnd Pharmakotherapie (DE-588)4076066-2 gnd |
| subject_GND | (DE-588)4127083-6 (DE-588)4073781-0 (DE-588)4076066-2 (DE-588)4143413-4 |
| title | Progress in Anti-Cancer Chemotherapy |
| title_auth | Progress in Anti-Cancer Chemotherapy |
| title_exact_search | Progress in Anti-Cancer Chemotherapy |
| title_full | Progress in Anti-Cancer Chemotherapy edited by David Khayat, Gabriel N. Hortobagyi |
| title_fullStr | Progress in Anti-Cancer Chemotherapy edited by David Khayat, Gabriel N. Hortobagyi |
| title_full_unstemmed | Progress in Anti-Cancer Chemotherapy edited by David Khayat, Gabriel N. Hortobagyi |
| title_short | Progress in Anti-Cancer Chemotherapy |
| title_sort | progress in anti cancer chemotherapy |
| topic | Oncology Cancer Research Oncology Chemotherapie (DE-588)4127083-6 gnd Krebs Medizin (DE-588)4073781-0 gnd Pharmakotherapie (DE-588)4076066-2 gnd |
| topic_facet | Oncology Cancer Research Oncology Chemotherapie Krebs Medizin Pharmakotherapie Aufsatzsammlung |
| url | https://doi.org/10.1007/978-2-8178-0920-5 |
| work_keys_str_mv | AT khayatdavid progressinanticancerchemotherapy AT hortobagyigabrieln progressinanticancerchemotherapy |